The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

NCT00483938 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Pegylated-interferon Alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche